Skip to Content

Notice

Advisory Committee Renewals

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Start Printed Page 50659charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table.

DATES:

Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.

Name of committeeDate of expiration
Advisory Committee for Pharmaceutical Science and Clinical PharmacologyJanuary 22, 2016.
Gastrointestinal Drugs Advisory CommitteeMarch 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)March 23, 2016.
April 5, 2016.
Arthritis Advisory CommitteeApril 25, 2016.
Pharmacy Compounding Advisory CommitteeMay 1, 2016.
Anesthetic and Analgesic Drugs Advisory CommitteeMay 13, 2016.
Blood Products Advisory CommitteeMay 30, 2016.
Pulmonary-Allergy Drugs Advisory CommitteeMay 31, 2016.
Drug Safety and Risk Management Advisory CommitteeJune 2, 2016.
Science Advisory Board to the National Center for Toxicological ResearchJune 4, 2016.
Peripheral and Central Nervous System Drugs Advisory CommitteeJune 4, 2016.
Psychopharmacologic Drugs Advisory CommitteeJune 9, 2016.
Transmissible and Spongiform Encephalopathies Advisory CommitteeJune 26, 2016.
Science Board to the Food and Drug AdministrationJuly 9, 2016.
Allergenic Products Advisory Committee
Start Further Info

FOR FURTHER INFORMATION CONTACT:

Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 1-800-741-8138. For further information related to FDA advisory committees please visit us at: http://www.fda.gov/​AdvisoryCommittees/​default.htm.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Start Signature

Dated: August 19, 2014.

Peter Lurie,

Associate Commissioner for Policy and Planning.

End Signature End Further Info End Preamble

[FR Doc. 2014-20017 Filed 8-22-14; 8:45 am]

BILLING CODE 4164-01-P